| Symbol | RNXT |
|---|---|
| Name | RENOVORX, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 4546 EL CAMINO REAL,SUITE B1, LOS ALTOS, California, 94022, United States |
| Telephone | +1 650 284-4433 |
| Fax | — |
| — | |
| Website | https://www.renovorx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001574094 |
| Description | RenovoRx Inc is a clinical-stage biopharmaceutical company. It is focused on developing therapies for the local treatment of solid tumors and conducting a Phase 3 registrational trial for lead product candidate RenovoGem. Additional info from NASDAQ: |
New Form S-8 - RenovoRx, Inc. <b>Filed:</b> 2026-06-30 <b>AccNo:</b> 0001493152-26-031320 <b>Size:</b> 255 KB
Read moreDirector RYAN UNA S 🟢 acquired 97.2K shares of RenovoRx, Inc. (RNXT) at $4.19 Transaction Date: Mar 03, 2022 | Filing ID: 029958
Read moreRenovoRx Highlights Peer-Reviewed Publication Supporting Intra-Arterial Gemcitabine Delivery Via TAMP™ in Locally Advanced Pancreatic Cancer
Read moreRenovoRx CEO, Shaun Bagai, to Present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 on June 23rd
Read moreRenovoRx CEO, Shaun Bagai, to Present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 on June 23rd
Read moreRenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic Cancer
Read moreRenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic Cancer
Read moreRenovoRx Announces Promising Pharmacokinetic Data Using theTAMP™ Platform Presented at the 2026 ASCO Annual Meeting
Read moreRenovoRx Announces Promising Pharmacokinetic Data Using the TAMP™ Platform Presented at the 2026 ASCO Annual Meeting
Read more